Decision to list patient warming and cooling medical devices supplied by EBOS Group Limited and Surgico Medical & Surgical Limited
13 March 2019
What we are doing
We are pleased to announce the approval of listing agreements with EBOS Group Limited (“EBOS”) and Surgico Medical & Surgical Limited (“Surgico”) for the supply of patient warming and cooling products.
In summary this will result in:
- EBOS and Surgico’s patient warming and cooling products being listed in Part III of Section H of the Pharmaceutical Schedule from 1 April 2019 under national agreements that all DHBs may purchase under (“Agreements”).
- DHBs continuing to be able to purchase other suppliers’ brands of patient warming and cooling products.
Any changes to the original proposal?
No changes have been made to the agreements as a result of consultation.
Who we think will be most interested
- Suppliers and Wholesalers
- DHB Staff:
- Anaesthetists and Anaesthetic Technicians
- Clinical engineers
- ICU Clinicians
- DHB procurement and warehousing personnel
Detail about this decision
The RFP was for non-exclusive national agreements for listing in the Pharmaceutical Schedule.
After completing the RFP evaluation process and consulting on the provisional Agreements reached with EBOS and Surgico PHARMAC has decided to list EBOS and Surgico’s range of patient warming and cooling products in Part III of Section H of the Pharmaceutical Schedule from 1 April 2019.
DHBs that purchase EBOS and Surgico’s patient warming and cooling products must do so under the terms and conditions and at the prices included in the Agreements, from 1 April 2019. DHBs can continue to choose which patient warming and cooling products they purchase.
The Agreements include terms and conditions for training, education and appropriate use of their products to be provided by EBOS and Surgico which is to be provided at times as agreed with individual DHBs.
Our response to what you told us
We appreciate the time people took to review this consultation. No feedback was received in relation to this proposal.
If you have any questions about this decision, you can email us at email@example.com; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Last updated: 20 November 2019